Exclusive: India seeks new preferential treatment from U.S. on drugs, other goods – sources

07/20/2020

|

Neha Arora|Aftab Ahmed|Reuters

NEW DELHI (Reuters) – India is seeking concessions for generic drugs it exports to the United States in return for opening its dairy markets and slashing tariffs on farm goods as the two sides seek to shore up a new trade deal, three sources said.

India accounts for 40% of U.S. generic drug imports, including the antimalarial hydroxychloroquine, touted by U.S. President Donald Trump in the fight against the coronavirus.

To win preferential treatment on pharmaceutical exports, the government of Prime Minister Narendra Modi is dangling the carrot of opening its dairy and farm markets to the Trump administration, months ahead of the U.S. presidential election.

“Americans recognize the political compulsion that brings its own benefits,” one of the sources with knowledge of the plans said.

India, one of the world’s largest consumers of dairy products, has offered an opening to U.S. dairy imports through a quota-based system, two of the sources said. These products would need a certificate they are not derived from animals that have consumed feeds that include internal organs, blood meal, or tissues of ruminants because of religious sensibilities in India.

India’s trade ministry did not immediately comment and the U.S. Embassy in New Delhi referred questions to the U.S. Trade Representative.

The two sides have been negotiating a limited trade pact for more than a year aimed at restoring zero tariffs on a range of Indian exports to the U.S. under its Generalised System of Preferences (GSP) that the Trump administration withdrew last year, citing lack of reciprocal access to India’s markets.

While India seeks concessions on drug exports, the United States has raised concerns over India’s import dependence on China for sourcing raw materials for generic drugs, Mukesh Aghi, president and chief executive at U.S.-India Strategic Partnership Forum, told Reuters.

Indian drugmakers rely on China, where the coronavirus was first identified at the end of last year, for almost 70% of the active pharmaceutical ingredients for their medicines.

“U.S. dependence on China indirectly is tied to India itself. And the U.S. is saying, if you want access to our market then become more self-sufficient than being dependent on China,” Aghi said.

To view the original article, please click here